Question 1

What is FOXO4-DRI?

Accepted Answer

FOXO4-DRI is a synthetic D-retro-inverso peptide studied as a senolytic, meaning it is designed to selectively clear senescent cells. It works by disrupting the FOXO4-p53 interaction so that p53 can trigger apoptosis in those cells. It is also written FOX04-DRI and sold by some vendors as Proxofim.

Question 2

What is FOXO4-DRI used for in research?

Accepted Answer

It is investigated mainly for cellular senescence and aging. Mouse and cell studies have looked at clearing senescent cells in aged tissue, testosterone-producing Leydig cells, cartilage chondrocytes, and blood-vessel endothelial cells. All current uses are preclinical research contexts, not approved treatments.

Question 3

How is FOXO4-DRI dosed?

Accepted Answer

The only published dosing protocol is from mouse studies: 5 mg/kg by intraperitoneal injection, given intermittently over weeks. No human dose has been established and no human trials exist. Community sources report a 16-week subcutaneous ladder of 250 mcg daily for Weeks 1-4, 375 mcg daily for Weeks 5-8, and 500 mcg daily for Weeks 9-16, but this is reported research context, not a recommendation.

Question 4

How do you reconstitute a 10 mg FOXO4-DRI vial?

Accepted Answer

Adding 3.0 mL of bacteriostatic water to a 10 mg vial gives about 3.33 mg/mL. On a U-100 insulin syringe, 7.5 units is about 250 mcg, 11.25 units is about 375 mcg, 15 units is about 500 mcg, and 30 units is about 1 mg. Use the calculator at peppal.app/calculator for other vial sizes.

Question 5

Is there a FOXO4-DRI dosage chart?

Accepted Answer

Yes, this guide includes a community-derived 16-week daily dosing ladder and a reconstitution chart for a 10 mg vial reconstituted with 3.0 mL of BAC water. It converts syringe units into micrograms and milligrams. Any chart is a research reference only, since no human dose has been validated.

Question 6

What are the observed effects of FOXO4-DRI?

Accepted Answer

There are no documented human observed effects because it has not been tested in people. Theoretical concerns include off-target cell death, immune burden from clearing many cells at once, impaired wound healing, and injection-site irritation. Product quality is a separate risk with this expensive-to-make peptide.

Question 7

Are there any FOXO4-DRI human trials?

Accepted Answer

No. As of June 2026 there are no completed or registered human clinical trials for FOXO4-DRI. All evidence comes from mouse models and cell cultures. ClinicalTrials.gov is the authoritative place to check if that ever changes.

Question 8

Is FOXO4-DRI FDA approved or legal?

Accepted Answer

FOXO4-DRI is not FDA approved and has no approved human indication. It is sold only as a research-use-only chemical and is not intended for human consumption. Laws vary by region, so verify local rules before purchasing.

Question 9

What is the FOXO4-DRI peptide sequence?

Accepted Answer

FOXO4-DRI is a D-retro-inverso peptide built from a FOXO4 fragment that binds p53, joined to a cell-penetrating sequence, with a molecular weight near 4.8 kDa. Published descriptions vary slightly in reported length, so for the exact chemical identity check the PubChem entry rather than relying on a single secondary source.

Question 10

Is FOXO4-DRI the same as Proxofim?

Accepted Answer

Proxofim is a name used by some research vendors for FOXO4-DRI. It refers to the same senolytic peptide. Listings sometimes appear as Proxofim 10 mg.

Question 11

Can FOXO4-DRI treat cancer?

Accepted Answer

No such claim can be made. Some preclinical work explores FOXO4-p53-targeting peptides against senescent cancer cells, and the developer has discussed cancer as a research interest, but there is no human evidence that FOXO4-DRI treats cancer. People with active cancer should be especially cautious.

Question 12

Is this page medical advice?

Accepted Answer

No. This is an educational research reference about FOXO4-DRI, not medical advice or a treatment plan. Talk with a qualified clinician before making decisions about any unapproved research compound.

Phase	Daily reference amount	Units / volume
Weeks 1–4	250 mcg	7.5 units (0.075 mL)
Weeks 5–8	375 mcg	11 units (0.11 mL)
Weeks 9–12	500 mcg	15 units (0.15 mL)
Weeks 13–16	500 mcg	15 units (0.15 mL)

FOXO4-DRI.

Calculated volume reference

Cited protocol & reconstitution guide